Saisei Ventures
Sven Kili is a seasoned professional with extensive experience in the cell and gene therapy sector. Currently serving as a Partner and Investment Advisor at Saisei Ventures since September 2023, Sven also leads SVEN KILI CONSULTING LTD as Principal, focusing on strategy and development for small and medium-sized companies in the field. Additionally, Sven holds significant roles, including Steering Committee Chair at UCL, Chair of the Cell & Gene Therapy Advisory Committee for the BioIndustry Association, and Chief Development Officer at CCRM. Previous positions include CEO of Antion Biosciences SA and VP at GSK, where responsibilities encompassed overseeing the development of advanced therapies. Sven Kili's educational background includes degrees in Medicine & Surgery and a Fellowship in Surgery.
This person is not in any teams
This person is not in any offices
Saisei Ventures
Saisei Ventures is a leading venture capital firm focused on growing and harnessing the Japanese biotech ecosystem; a region rich in opportunities and potential. We create ventures that start from bold ideas and empower dynamic entrepreneurs by filling in technical, operational, or financial gaps. Our approach combines Western expertise and Japanese innovation to build globally competitive companies that will have the greatest impact on patient lives.